Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for mo… Read more
Verrica Pharmaceuticals Inc (VRCA) - Total Assets
Latest total assets as of September 2025: $40.90 Million USD
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) holds total assets worth $40.90 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Verrica Pharmaceuticals Inc - Total Assets Trend (2016–2024)
This chart illustrates how Verrica Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Verrica Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verrica Pharmaceuticals Inc's total assets of $40.90 Million consist of 94.5% current assets and 5.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.6% |
| Accounts Receivable | $77.00K | 0.1% |
| Inventory | $2.46 Million | 4.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Verrica Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verrica Pharmaceuticals Inc's current assets represent 94.5% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 85.6% of total assets in 2024, down from 96.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 4.6% of total assets.
Verrica Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Verrica Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Verrica Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Verrica Pharmaceuticals Inc generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Verrica Pharmaceuticals Inc is currently not profitable relative to its asset base.
Verrica Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.34 | 1.71 |
| Quick Ratio | 1.18 | 1.22 | 1.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.37 Million | $ 7.16 Million | $ 28.18 Million |
Verrica Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Verrica Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 238.54 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | -33.7% |
| Total Assets | $54.13 Million |
| Market Capitalization | $20.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Verrica Pharmaceuticals Inc's assets below their book value (0.39 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Verrica Pharmaceuticals Inc's assets decreased by 33.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Verrica Pharmaceuticals Inc (2016–2024)
The table below shows the annual total assets of Verrica Pharmaceuticals Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $54.13 Million | -33.66% |
| 2023-12-31 | $81.60 Million | +82.46% |
| 2022-12-31 | $44.72 Million | -44.19% |
| 2021-12-31 | $80.12 Million | +8.05% |
| 2020-12-31 | $74.15 Million | +8.37% |
| 2019-12-31 | $68.42 Million | -25.55% |
| 2018-12-31 | $91.91 Million | +911.85% |
| 2017-12-31 | $9.08 Million | +1569.67% |
| 2016-12-31 | $544.00K | -- |